Incidence of Pericardial Effusion in Patients with Advanced Non-Small Cell Lung Cancer Receiving Immunotherapy
Maria Laura Canale, Andrea Camerini, Giancarlo Casolo, Alessio Lilli, Irma Bisceglia, Iris Parrini, Chiara Lestuzzi, Jacopo Del Meglio, Cheti Puccetti, Lara Camerini, Domenico Amoroso & Nicola Maurea
Given the potentially fatal consequence of cardiovascular toxicity due to immunotherapy in this study researchers retrospectively analyzed a group of patients with non-small cell lung cancer (NSCLC) to look for the presence of pericardial effusion before and after treatment with either nivoumab or pembrolizumab.
Their findings confirmed that pericardial effusion is a frequent toxicity in patients with metastack NSCLC receving immunotherapy.
© All Rights Reserved